Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health reported one-year REMAIN-1 data showing Revita reduced weight regain after GLP-1 therapy with favorable safety results.
Read original at benzingaStocks · News reference
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of $(0.57) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 8:07 PM
- Checked
- Aug 10, 2026, 8:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Fractyl Health shares are trading higher after the company announced randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation.
Read original at benzingaFractyl Health Announces One-Year Results From Its REMAIN-1 Midpoint Cohort; Results Reinforce Potential Of Revita DMR System To Become First Durable Therapy For Post-GLP-1 Weight Maintenance
Key Findings:Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one
Read original at benzinga